Close Menu

NEW YORK ─ Bagneux, France-based biotech firm Genomic Vision announced on Tuesday that it has inked a contract to distribute two rapid diagnostic tests for SARS-CoV-2, called Toda Coronadiag+ and Coronadiag Ag, manufactured by Toda Pharma.

Financial and other terms of the agreement were not disclosed.

The Coronadiag Ag test enables the detection of coronavirus antigens from nasopharyngeal or oropharyngeal samples, offering an alternative to PCR tests. It is effective from one to seven days after the onset of symptoms or after a suspected infection, Genomic Vision said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.